FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washing

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

gton, D.C. 20549	
Jion, D.C. 20049	OMB APPROVAL
	OND AFFROVAL

OMB Number:	3235-0287
Estimated average burde	en

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PDL BIOPHARMA, INC.					2. Issuer Name and Ticker or Trading Symbol Evofem Biosciences, Inc. [EVFM]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
FDL D	IOFIIAIN	MA, IIIC.								_				Director		X	10% Ow	ner		
													_	Officer (g	jive title		Other (sp	ecify		
(Last)	(F	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)									below)			below)			
932 SOUTHWOOD BOULEVARD					06/10/2019															
(Street)				— -	1 If Am	andmont C	Note of	Original F	ilad (Month/Do	(\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		6 Indi	vidual or Toi	nt/Croup I	Filipa ((Chook Applie	ooble Line)		
INCLINE NV 89451 VILLAGE				4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
												A	Form filed by More than One Reporting Person				ng Borcon			
				—— I										roilli ille	u by wore	uian	one Reportii	ig Feison		
(City)	(5	State)	(Zip)																	
		Ţ	able I - Non	-Deriva	tive S	ecuritie	s Ac	quired,	Disp	osed o	of, or E	Bene	ficially (Owned						
Date				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		e, Transaction Disposed Code (Instr.		ities Acquired (A) o d Of (D) (Instr. 3, 4 a			and 5) Securities Beneficial		Form: (D) or	Direct Indirect E	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
													Owned Following Reported		(I) (Instr. 4)					
								Code	V	Amount		A) or O)	Price	Transactio (Instr. 3 an			ľ			
Common Stock 06				06/10/2	0/2019			P		6,666,667		Α	\$4.5	13,333,334			D			
			Table II - I	Derivati	ve Se	curities	Acai	uired. D	ispo	sed of	. or Be	nefi	cially O	wned			•			
						lls, warr														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou Securities Underl Derivative Securi (Instr. 3 and 4)		derlying curity	rlying Derivative		S Form Ally Direction or In G (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)		Date Exercisabl		xpiration ate	Title	Nι	nount or imber of iares		Transact (Instr. 4)					
Warrants (Right to Buy)	\$6.38	06/10/2019		A		1,666,667		12/10/201	00	6/10/2026	Commo Stock		666,667	(1)	1,666,	667	D			

Explanation of Responses:

Remarks:

/s/ Peter S. Garcia, Chief Financial Officer of PDL

06/10/2019

BioPhram, Inc.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} Pursuant to that certain Securities Purchase Agreement, dated as of April 10, 2019, by and among the Issuer, the Reporting Person and the other parties thereto, on June 10, 2019, the Reporting Person purchased 6,666,667 shares of Common Stock of the Issuer, at a price of \$4.50 per share, and received warrants to purchase up to an additional 1,666,667 shares of Common Stock for an aggregate purchase price of approximately \$30.0 million.